About Galectin-9
Galectin-9 (LGALS9) is a protein
from Homo sapiens identified by UniProt accession
O00182, 355 residues long.
MolForge cross-references it against 0 known binders and
561 disease associations.
Target properties
| Protein name | Galectin-9 |
|---|
| UniProt accession | O00182 |
|---|
| Gene | LGALS9 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 355 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (561)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.41
- neurodegenerative disease · score 0.35
- glioblastoma multiforme · score 0.21
- eosinophil count · score 0.19
- breast adenocarcinoma · score 0.18
- inflammatory bowel disease · score 0.13
- neoplasm · score 0.12
- Red cell distribution width · score 0.12
- Rheumatoid arthritis · score 0.11
- acute myeloid leukemia · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O00182-F1 | alphafold | PREDICTED | 84.91 | — |
Amino-acid sequence (355 residues)
MAFSGSQAPY LSPAVPFSGT IQGGLQDGLQ ITVNGTVLSS SGTRFAVNFQ TGFSGNDIAF HFNPRFEDGG YVVCNTRQNG SWGPEERKTH MPFQKGMPFD LCFLVQSSDF KVMVNGILFV QYFHRVPFHR VDTISVNGSV QLSYISFQNP RTVPVQPAFS TVPFSQPVCF PPRPRGRRQK PPGVWPANPA PITQTVIHTV QSAPGQMFST PAIPPMMYPH PAYPMPFITT ILGGLYPSKS ILLSGTVLPS AQRFHINLCS GNHIAFHLNP RFDENAVVRN TQIDNSWGSE ERSLPRKMPF VRGQSFSVWI LCEAHCLKVA VDGQHLFEYY HRLRNLPTIN RLEVGGDIQL THVQT
Explore Galectin-9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets